First Biotherapeutics Co., Ltd. (CEO Jae-eun Kim, hereinafter referred to as First Bio) announced on the 2nd that it has been selected for the 2025 Ministry of SMEs and Startups' 'Global Enterprise Collaboration Program' for the second consecutive year.
This selection follows the first stage of the project carried out last year, and this year, excellent graduate companies will participate in the second stage of the program, which aims to strengthen AI-based new drug development capabilities and accelerate entry into the global market.
The 'Global Enterprise Collaboration Program' is a public-private partnership project that collaborates with leading global companies to support the global expansion of domestic startups. Since 2019, 13 global companies, including Dassault Systèmes, Nvidia, and Microsoft, have participated. Starting this year, a new two-stage program has been introduced for graduating companies with excellent performance.
Last year, FirstBio was selected as a global collaboration excellence company by collaborating with AI virtual twin company Dassault Systèmes to complete the first phase of the project. This year, it was selected for the second phase of the project, once again proving its AI-based drug discovery technology and growth potential.
In this collaboration, FirstBio will conduct drug efficacy evaluation research through molecular binding analysis, molecular dynamics simulation, etc. with Dassault Systèmes’ BIOVIA Contract Research team. Through this, it plans to focus on enhancing the structure-based drug design function of its unique AI drug discovery platform and improving prediction accuracy. In addition, it plans to internalize technology trends in the AI field and strengthen connections with the global market through participation in various networking events and conferences.
Kim Jae-eun, CEO of FirstBio, said, “We have been recognized for our AI-based drug discovery technology that we have accumulated over the years and the potential of our early discovery platform.” He added, “Based on our collaboration with global company Dassault Systèmes, we will increase the speed and efficiency of innovative new drug development and create value through the convergence of AI and biotechnology in the global market.”
- See more related articles
You must be logged in to post a comment.